Surfing the MASH Tsunami

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(1073)

S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?

S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?

Send us Fan Mail This week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with cirrhosis. While the immediate stimulus for ...

23 Jul 202211min

S3-E37.1 - Cirrhosis Screening & Diagnostic Tests

S3-E37.1 - Cirrhosis Screening & Diagnostic Tests

Send us Fan Mail This week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with cirrhosis. While the immediate stimulus for ...

23 Jul 20229min

S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?

S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?

Send us Fan Mail Surfing the NASH Tsunami has explored issues of NASH cirrhosis since our earliest episodes in 2020. This episode integrates panelists with three different perspectives to consider the...

21 Jul 202255min

S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...

17 Jul 202213min

S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...

17 Jul 202212min

S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...

16 Jul 202212min

S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients

S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients

Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...

16 Jul 202214min

S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...

16 Jul 202213min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
liberal-halvtime
jss
sinnsyn
forskningno
dekodet-2
fjellsportpodden
villmarksliv
abels-tarn
rss-overskuddsliv
rss-nysgjerrige-norge
rss-paradigmepodden
rss-inn-til-kjernen-med-sunniva-rose
diagnose
tomprat-med-gunnar-tjomlid
rss-rekommandert
rss-lundqvist-podden
kvinnehelsepodden